Sasho Ganov, general manager at BB–NCIPD (BulBio), explains the role of the company in the national health system as the only state-owned enterprise in Bulgaria as well as shares his ambitions moving forward in support with its recently built laboratory/manufacturing site.
Could you please introduce to our international audience the history as well as the main responsibilities of BulBio?
"One of my main priorities as general manager of BulBio is to develop the production capabilities of our BCG vaccine since there is a huge and unsatisfied global need in this area."
